Skip to main content
. 2020 May 1;13(5):954–963.

Figure 2.

Figure 2

ME-MSC transplantation ameliorated SFR in NOD/Ltj mice. A. Blood glucose levels of mice 12 weeks before ME-MSC treatment. NOD/Ltj mice became hyperglycemia since the 10-week-old, while blood glucose concentration in ICR mice was normal. B. SFR of mice 12 weeks before ME-MSC treatment. SFR in NOD/Ltj mice decreased since the 9-week-old compared with that in ICR mice (P<0.05). C. SFR of mice 2 weeks after ME-MSC treatment. 12-week-old NOD mice were injected intraperitoneally with. 2 weeks after ME-MSC treatment, the mouse SFR in disease group [(47.8±12.4) μg/min, n=9] was distinctly decreased compared with that in the treatment group [(93.1±12.2) μg/min, n=11] (P<0.05), but SFR in treatment group was still lower than that in the healthy control group [(247.8±18.0) μg/min, n=3] (P<0.05). D. SFR of mice 2 weeks after ME-MSC treatment. After ME-MSC treatment, SFR in treatment group was slightly decreased. However, SFR in treatment group was still better than that in disease group. *P<0.05.